Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MESO vs KURA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MESO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–3 Matrix Metrics)

MESO Overall Winner 6-Pillar Tally: MESO 3 – 2 KURA (1 Tie) Matrix Metrics: MESO 5 – 3 KURA

As of Nov 16, 2026, Mesoblast Limited (MESO) is the stronger overall head-to-head candidate over Kura Oncology, Inc. (KURA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas KURA carries 64.1/100 (BUY) at $7.30 (N/M Forward P/E, -394.3% operating margin).

  • Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (64.1/100 BUY vs. MESO 34.6/100 SELL), MESO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-42.6% vs. -394.3% operating margin) and revenue trajectory (+390.7% vs. +10.1% YoY).
  • Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile KURA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MESO vs KURA
MESO NASDAQ Head-to-Head Winner
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
34.6 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $13.64 · SMA50: $14.22
KURA NASDAQ
Kura Oncology, Inc.
Pharmaceutical Preparations
$7.30
-6.05% 1D
Market Cap $690.9M
TTM Revenue $79M
Forward P/E N/M
Beta / 30D Vol 1.42β · 108% Vol
Unified Composite Score
64.1 / 100 BUY
Tech 63.0 Fund 64.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.2%), weak momentum, RSI 35
RSI-14: 34.8 · SMA20: $8.86 · SMA50: $10.05

6-Pillar Scorecard Institutional Category Breakdown (MESO 3 – 2 KURA)

Columns: Metric · MESO · KURA
1. Valuation Multiples KURA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 14.1x 8.3x
2. Growth & Scale MESO
Revenue Growth (YoY) +390.7% +10.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $120M $79M
Market Cap $1.7B $690.9M
3. Profitability & Quality MESO
Gross Margin 80.0% N/A
Operating Margin -42.6% -394.3%
Net Profit Margin -47.8% 0.0%
Return on Equity (ROE) -9.9% -224.8%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$45M EBITDA -$89M
Cash Flow Margin -37.1% EBITDA Mgn -112.4%
Net Cash / Leverage $4.38 Book/Sh · -9.9% ROE $32M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KURA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 76.8% (37th %ile) 103.8% (20th %ile)
Put/Call OI Skew Thin ADR Chain 1.50x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MESO (5) vs KURA (3)
Institutional Metric MESO KURA Criterion Row Edge
Market Capitalization
Scale
$1.7B $690.9M Larger Scale MESO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+390.7% +10.1% Higher Growth MESO
Operating Margin (TTM)
Profitability
-42.6% -394.3% Higher Margin MESO
Net Profit Margin
Profitability
-47.8% 0.0% Higher Margin KURA
Return on Equity (ROE)
Capital Efficiency
-9.9% -224.8% Higher ROE MESO
52-Week Range Position
Momentum
6% ($12–$22) 8% ($7–$14) Stronger Trend KURA
Beta / 30D Volatility
Risk Regime
1.18β · 78% Vol 1.42β · 108% Vol Lower Realized Risk MESO
Unified Institutional Score
Composite Signal
34.6 / 100 (SELL) 64.1 / 100 (BUY) Higher Composite KURA
Trailing 12M Revenue (USD)
Operating Scale
$120M $79M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
80.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.1x EV/Rev N/M PEG · 8.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) -$89M ($32M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MESO +13.5 pp
MESO: -6.1% · KURA: -19.6%
3M Horizon MESO +15.6 pp
MESO: -25.19% · KURA: -40.79%
6M Horizon MESO +5.83 pp
MESO: -14.82% · KURA: -20.65%
1Y Horizon MESO +15.23 pp
MESO: -16.42% · KURA: -31.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs KURA. Trailing 12-month operating profitability (MESO -42.6% vs KURA -394.3%) and valuation multiples (MESO N/M vs KURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M
KURA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$79M
Gross MarginN/A
Op. Margin-394.3%
ROE / Fwd P/E-224.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KURA BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 103.8%
IV Percentile 20th %ile
Put/Call OI Skew 1.50x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact KURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $690.9M market capitalization and -394.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MESO vs KURA Key Questions & Quantitative Answers

As of Nov 16, 2026, Mesoblast Limited (MESO) is the stronger overall head-to-head candidate over Kura Oncology, Inc. (KURA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas KURA carries 64.1/100 (BUY) at $7.30 (N/M Forward P/E, -394.3% operating margin). Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (64.1/100 BUY vs. MESO 34.6/100 SELL), MESO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-42.6% vs. -394.3% operating margin) and revenue trajectory (+390.7% vs. +10.1% YoY). Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile KURA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: MESO posts +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin), compared with KURA at +10.1% YoY revenue growth and +0.0% YoY earnings growth on $79M TTM revenue (N/A gross margin, -394.3% operating margin). On trailing 12-month operating scale, MESO generates $120M in USD-normalized revenue versus $79M for KURA. In operating R&D and SG&A reinvestment, MESO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KURA.

KURA screens cheaper on headline valuation multiples. MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin), whereas KURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.3x EV/Revenue (-112.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MESO (-9.9% ROE) versus KURA (-224.8% ROE) capital efficiency.

In options market volatility and institutional positioning, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk). By comparison, KURA carries 103.8% implied volatility (20th %ile, Compressed (<25th %ile)), a 1.50x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 108% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.